EMA’s CHMP Recommends Yervoy for Patients 12 and Older with Advanced Melanoma

Source: Immuno-Oncology News, December2017

Yervoy (ipilimumab) has received a positive review by the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of unresectable or metastatic melanoma in patients age 12 and older.
The CHMP’s recommendation will now be reviewed by the European Commission, the authority that approves medicines for the European Union.
“Pediatric melanoma is a particularly rare cancer, with limited treatment options for children in the E.U. impacted by the disease,” Murdo Gordon, executive vice president and chief commercial officer at Bristol-Myers Squibb, said in a press release.